These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18423992)

  • 1. Exploring the anti-tumour activity of bisphosphonates in early breast cancer.
    Winter MC; Holen I; Coleman RE
    Cancer Treat Rev; 2008 Aug; 34(5):453-75. PubMed ID: 18423992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
    Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antitumour effects of bisphosphonates in breast cancer].
    van de Ven S; Kroep JR; Hamdy NA; Sleeboom HP; Nortier HW
    Ned Tijdschr Geneeskd; 2010; 154():A1951. PubMed ID: 21083955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates in the adjuvant treatment of breast cancer.
    Winter MC; Coleman RE
    Clin Oncol (R Coll Radiol); 2013 Feb; 25(2):135-45. PubMed ID: 23207072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential anticancer properties of bisphosphonates.
    Neville-Webbe HL; Gnant M; Coleman RE
    Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects and anticancer applications of bisphosphonates.
    Morgan G; Lipton A
    Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour activity of zoledronic acid.
    Clézardin P
    Cancer Treat Rev; 2005; 31 Suppl 3():1-8. PubMed ID: 16225995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
    Coleman RE
    Eur J Cancer; 2009 Jul; 45(11):1909-15. PubMed ID: 19447606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of bisphosphonates in breast cancer.
    Coleman RE
    Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates in breast cancer: antitumor effects.
    Aft R
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for the prevention of bone metastases.
    Coleman RE
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the horizon: can bisphosphonates prevent bone metastases?
    Coleman R
    Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease.
    Neville-Webbe HL; Coleman RE
    Eur J Cancer; 2010 May; 46(7):1211-22. PubMed ID: 20347292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid for adjuvant use in patients with breast cancer.
    Ressler S; Mlineritsch B; Greil R
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):333-49. PubMed ID: 21417849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
    Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antitumor potential of bisphosphonates.
    Clézardin P
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.